head JofIMAB
Journal of IMAB
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2024, vol. 30, issue2
Subject Area: Medicine
-
DOI: 10.5272/jimab.2024302.5545
Published online: 30 May 2024

Original articlet
J of IMAB. 2024 Apr-Jun;30(2):5545-5551
USE OF MISOPROSTOL IN ABORTION ON MEDICAL GROUNDS – OUR CLINICAL EXPERIENCE
Zhivko Zhekov1, 2ORCID logoCorresponding Autoremail, Svetlana Radeva1, 3ORCID logo,
1) Specialized hospital of obstetrics and gynecology for active treatment – Varna, Bulgaria.
2) Department of Obstetrics and Gynecology, Medical University of Varna, Bulgaria.
3) Department Health care, Faculty of Public Health, Medical University of Varna, Bulgaria.

ABSTRACT:
Purpose. In clinical practice in hospital conditions, the preferred choice of behavior regarding fetal anomalies is to perform a medical abortion after the opinion of a specialized committee in the hospital. There are no observations conducted by other authors on abortions related to termination of pregnancy for medical reasons at a different time. The team conducts its observation in hospital conditions.
Material/Methods: Conducted own retrospective study for the period January 2021 – February 2024 with the participation of 45 patients who went through a pregnancy termination committee on medical grounds. All women who passed through the committee for medically indicated abortion, in which fetal anomalies incompatible with life or severely debilitating were found, were examined. Women are at different stages of pregnancy, age, education, number of pregnancies and births, concomitant diseases, a type of test to diagnose abnormalities in the fetus (invasive and non-invasive). The type of abnormality that is the cause of an abortion on medical grounds has also been investigated. The dosage applied is- 1st tablet of 400 mg Misoprostol per vagine, second and third tablets in 3 hours sub buccal, the maximum dose is 5 tablets in 24 hours or 2000 microgram Misoprostol.
Results. For 88,9% of the cases, they have a positive opinion of the commission in the hospital structure, and 11,1% have a refusal. Group matching of patients was performed by education and whether they had good outpatient follow-up, regardless of the duration of pregnancy. Patients with higher education had better outpatient follow-up (χ2=15.497, p=0.000) than those with secondary and primary education. There was a significant association between the dosing regimen and pregnancy severity; the relationship between the two-dose regimen was significant (χ2=53.862, p=0.000), and the three-dose regimen was highly successful in 73.3% of cases.
Conclusion. The correct choice of method of application of the therapeutic regimen requires preliminary and detailed medical preparation of the patient and good clinical experience of the treating doctor. The applied therapeutic approach reduces the risk to the patient and has a rapid recovery period. Early and timely diagnosis has an important informative value.

Keywords: malformations, prenatal diagnosis, Commission medical abortion, Misoprostol, therapeutic scheme,

pdf - Download FULL TEXT /PDF 1218 KB/
Please cite this article as: Zhekov Z, Radeva S. Use of Misoprostol in abortion on medical grounds – our clinical experience. J of IMAB. 2024 Apr-Jun;30(2):5545-5551. [Crossref - 10.5272/jimab.2024302.5545]

Corresponding AutorCorrespondence to: Zhivko Zhekov, Specialized hospital of obstetrics and gynecology for active treatment, Varna; Department of Obstetrics and Gynecology, Medical University of Varna; 150, Tcar Osvoboditel Blvd., 5000 Varna, Bulgaria; E-mail: azhivko61@abv.bg

REFERENCES:
1. Baird DT. Medical abortion in the first trimester. Best Pract Res Clin Obstet Gynaecol. 2002 Apr;16(2):221-36. [PubMed ]
2. Bracken H, Ngoc NT, Schaff E, Coyaji K, Ambardekar S, Westheimer E, et al. Mifepristone followed in 24 hours to 48 hours by Misoprostol for late first-trimester abortion. Obstet Gynecol. 2007 Apr;109(4):895-901. [PubMed]
3. Løkeland M, Bjørge T, Iversen OE, Akerkar R, Bjørge L. Implementing medical abortion with mifepristone and Misoprostol in Norway 1998-2013. Int J Epidemiol. 2017 Apr 1;46(2):643-651. [PubMed]
4. Løkeland M, Iversen OE, Engeland A, Økland I, Bjørge L. Medical abortion with mifepristone and home administration of Misoprostol up to 63 days' gestation. Acta Obstet Gynecol Scand. 2014 Jul;93(7):647-53. [PubMed].
5.Bebbington MW, Kent N, Lim K, Gagnon A, Delisle MF, Tessier F, Wilson RD. A randomized controlled trial comparing two protocols for the use of Misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol. 2002 Oct;187(4):853-7. [PubMed]
6. Misoprostol Only Recommended Regime. Obstetrics and Gynecology consultative committee, FIGO. March, 27th, 2018. [Internet]
7. Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal Misoprostol for early abortion. Eur J Contracept Reprod Health Care. 2000 Sep;5(3):171-6. [PubMed]
8. NAF Protocol for Mifepristone/Misoprostol in Early Abortion. NAF. April 2016. [Internet]
9.  Safe abortion: technical and policy guidance for health systems. Second edition. WHO. 19 June 2012. [Internet]
10. Chakravarti IM, Laha RG, Roy J. Handbook of Methods of Applied Statistics. Volume I. John Wiley and Sons, Hoboken. 1967. pp. 392-394.
11. Briozzo L, Gómez Ponce de León R, Tomasso G, Faúndes A. Overall and abortion-related maternal mortality rates in Uruguay over the past 25years and their association with policies and actions aimed at protecting women's rights. Int J Gynaecol Obstet. 2016 Aug;134 Suppl 1:S20-3. [PubMed]
12. Foster AM, Arnott G, Hobstetter M. Community-based distribution of Misoprostol for early abortion: evaluation of a program along the Thailand-Burma border. Contraception. 2017 Oct;96(4):242-247. [PubMed]
13. Stillman M, Owolabi O, Fatusi AO, Akinyemi AI, Berry AL, Erinfolami TP, Olagunju OS, et al. Women's self-reported experiences using Misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria. BMJ Open, 2020 May 5;10(5):e034670. [PubMed]
14. Akinyemi A, Owolabi OO, Erinfolami T, Stillman M, Bankole A. Quality of information offered to women by drug sellers providing medical abortion in Nigeria: Evidence from providers and their clients. Front Glob Womens Health. 2022 Aug 17;3:899662. [PubMed]
15.  Krugh M, Maani CV. Misoprostol. 2023 Apr 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. [PubMed]

Received: 22 February 2024
Published online: 30 May 2024

back to Online Journal